R(
Therapeutic Areas
NGM Biopharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| NGM120 | Hyperemesis Gravidarum | Phase 2 |
| NGM831 (MK-3655) | Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Phase 2b |
| NGM621 | Geographic Atrophy (GA) | Phase 2 |
| NGM438 | Genetic Lipodystrophy | Preclinical |